MedTrace Logo

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

NCT01519778 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2018-08-29

Study results available
· View outcomes & findings →

Summary

Characterization of the safety profile of TR-701 Free Acid (FA) in patients with major cutaneous abscess or cellulitis/erysipelas.

Conditions

  • Major Cutaneous Abscess
  • Cellulitis
  • Erysipelas

Interventions

DRUG

TR701 FA

1 tablet 200 mg once daily

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

    lead INDUSTRY

Principal Investigators

  • Philippe Prokocimer, MD · Trius Therapeutics

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-15
Primary Completion
2012-08-27
Completion
2012-08-27

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01519778 on ClinicalTrials.gov